<DOC>
	<DOCNO>NCT02169037</DOCNO>
	<brief_summary>This prospective randomized study assess safety efficacy FIRM ( Focal Impulse Rotor Modulation ) -guided ablation treatment symptomatic atrial fibrillation ( AF ) . The study hypothesis efficacy AF elimination 1 year high ablate patient-specific AF-sustaining rotor focal source Focal Impulse Rotor Modulation ( FIRM ) compare conventional ablation alone ( wide-area PV isolation ) .</brief_summary>
	<brief_title>Substrate Versus Trigger Ablation Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>Pulmonary vein isolation ( PVI ) standard care therapy atrial fibrillation ( AF ) . However , produce suboptimal result , single procedure success 45-55 % , multiple procedure success rate 65-75 % recent randomized trial . The rationale PVI eliminate trigger Pulmonary vein . An alternative strategy eliminate substrate sustain AF trigger , apply arrhythmia . However , relevance AF substrates - least persistent AF - question recent STAR-AF-II trial , ablate additional line complex atrial electrograms ( CFAE ) improve success PVI alone ( Verma et al. , 2015 ) - although success remain ~50 % single procedure . Because STAR-AF2 , PVI limb trial PVI alone ( wide area circumferential ablation ) additional lesion . Focal Impulse Rotor Modulation ( FIRM ) novel approach eliminate specific electrical substrate AF , demonstrate study many laboratory take form localize electrical circuit . These rotor focal source lie patient-specific location , often away typical PVI ablation site right atrium , ablate substantially improve single procedure success rate PVI several multi center non-randomized trial ( Narayan , J Am Coll Cardiol . 2012 ; Miller , J Cardiovasc Electrophysiol . 2014 ) . There therefore equipoise literature PVI alone , long-history suboptimal result , FIRM , new potentially great efficacy without randomize trial data . This study test strategy randomize controlled fashion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>INCLUSION CRITERIA : male female &gt; 21 year report incidence least two documented episode symptomatic paroxysmal atrial fibrillation ( AF ) three month precede trial entry ( least 1 episode document 12lead ECG ECG rhythm strip ) woman without childbearing potential woman childbearing potential pregnant per serum HCG test refractory least one Class I III antiarrhythmic medication . Drug dose must therapeutic stable willingness , ability commitment participate baseline followup evaluation without participation another clinical trial ( unless document approval receive sponsor ) oral anticoagulation require subject score two base follow criterion ( CHAD score ) : Congestive heart failure ( 1 point ) hypertention ( 1 point ) age 75 year old ( 2 point ) diabetes ( 1 point ) prior stroke transient ischemic attack ( 2 point ) vascular disease ( 1 point ) age 65 year old ( 1 point ) sex category : female ( 1 point ) patient willing able remain anticoagulation therapy minimum 3 month post procedure subject , potentially indefinitely post procedure patient CHAD score &gt; or=2 sign informed consent full discussion risk benefit therapy arm , concept randomization NYHA Class 0 , I , II stable medical therapy &gt; 3months leave atrial diameter &lt; or= 5.5cm LVEF &gt; or=40 % sustain AF procedure EXCLUSION CRITERIA : atrial fibrillation reversible cause ( e.g. , surgery , hyperthyroidism , pericarditis ) cardiac thoracic surgery within past 180 day AF secondary electrolyte imbalance , thyroid disease contraindication Heparin Contraindication Warfarin novel oral anticoagulant history significant bleeding abnormality history significant blood clot abnormality , systemic thrombus systemic embolization ASD closure device , LAA closure device , prosthetic mitral tricuspid valve atrial clot/thrombus image transesophageal echocardiogram ( TEE ) within 72 hour procedure intramural thrombus cardiac mass may adversely effect catheter introduction manipulation significant pulmonary embolus within 6 month enrollment acute illness active systemic infection sepsis may ordinarily warrant postponement procedure history recent cerebrovascular disease ( stroke TIA ) systemic thromboembolism within &lt; 6 month NYHA class III , IV heart failure stable medical therapy pulmonary edema , may make planned anesthesia sedation difficult stable/unstable angina ongoing myocardial ischemia myocardial infarction ( MI ) within past three month structural heart disease clinical significance include : congenital heart disease abnormality correction prohibit increase risk ablation acquire heart disease may increase risk ablation , significant ventricular septal defect post myocardial infarction rheumatic valve disease , since produce unique AF phenotype extreme leave atrial enlargement ( LA volume index &gt; 60 ml/m2 ) PVI low success 55 mm basket small atrium cardiac transplantation cardiac surgery plan within 12 month followup period trial life expectancy le 12 month ( followup period trial ) significant pulmonary disease ( e.g. , COPD ) disease significantly increase risk patient sedation anesthesia untreatable allergy contrast medium time ablation procedure , clinically significant abnormality serum potassium , sodium , magnesium electrolyte affect suitability patient ablation time</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Rotor</keyword>
	<keyword>FIRM</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Atrial tachyarrhythmia</keyword>
	<keyword>Ablation</keyword>
	<keyword>Contact mapping</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Signal processing .</keyword>
</DOC>